The third Presidential Symposium of ESMO 2019 included results with targeted therapies in cholangiocarcinoma and prostate cancer, and immunotherapy for oesophageal and urothelial carcinoma.
- Advanced cholangiocarcinoma: ivosidenib vs placebo in patients with IDH1 mutations:
- Median PFS was 2.7 vs 1.4 months with placebo (HR 0.37) with a disease control rate of 53% vs 28%.
- Median OS (10.8 vs 9.7 months with placebo) did not reach significance, possibly due to crossover.
- Second-line nivolumab versus chemotherapy in advanced oesophageal squamous cell carcinoma (ESCC):
- Primary endpoint of OS was met with 10.9 vs 8.4 months with chemotherapy (HR 0.77).
- Nivolumab had lower ORR (19% vs 22%) and PFS (1.7 vs 3.4 months), but a longer duration of response (6.9 vs 3.9 months).
- Olaparib versus androgen-receptor targeted therapy (ART) for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations:
- Study stratified patients into BRCA1/2 or ATM mutations (cohort A) and any of 12 other HRRs (cohort B).
- Primary endpoint of radiological PFS (rPFS) in cohort A was met with 7.39 vs 3.55 months with control (HR 0.34).
- Full coverage on Univadis.
- Randomised, open-label study of cabazitaxel vs ART in mCRPC:
- Primary endpoint rPFS was 8.0 vs 3.7 months with ART therapy (HR 0.54).
- OS also improved (13.6 vs 11.0 months, HR 0.64), even though the trial allowed crossover.
- Atezolizumab as monotherapy or combined with platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC):
- Three-arm study with atezolizumab+platinum-based chemotherapy (A), atezolizumab monotherapy (B), or placebo plus chemotherapy (C).
- Arms A vs Arm C PFS was 8.2 vs 6.3 months (HR 0.82). Arm B vs Arm C comparisons showed interesting differences based on PD-L1 level.